About test

Experience the future of cancer diagnostics with liquid biopsy

The HP2 circulating tumor DNA test is a non-invasive, highly sensitive and comprehensive test that simplifies tumor detection and cancer treatment monitoring for all patients.

What is the HP2 test?

The HP2 circulating tumor DNA test is a liquid biopsy test that examines the DNA of key cancer genes circulating in the blood plasma. A 32-gene panel is tested using next-generation sequencing to detect a variety of cancer types.

The test is performed from venous blood. The gene panel detects clinically important cancer gene alterations with extremely high sensitivity.

The HP2 (Hedera Profiling 2) test was developed by the Swiss company Hedera Dx GmbH.

The HP2 test shows:

Untitled design (14)

Tumor molecular type

Untitled design (15)

Possible personalized therapy

Why is it worth performing the HP2 test?

Simple

A venous blood sample is sufficient for a detailed tumor analysis – no surgical interventions are required.

Comprehensive

The molecular composition of the tumor is determined, which allows pathologists and doctors to know how to effectively treat it and how quickly the tumor develops or disappears.

Reliable

The test is performed in the modern Hedera Dx certified Saidė Genomics laboratory in Lithuania, operating in accordance with ISO 15189:2023 requirements.

Accurate

The sensitivity and specificity for SNV/InDel detection are >96% and >99%, respectively, and for gene fusions, the sensitivity and specificity are 100%. Microsatellite instability (MSI) with a VAF of ≥1% and CNVs with a VAF of ≥2% are detected with 100% sensitivity* [1].

Personalised

Patients can be offered effective therapies tailored to their unique tumor, improving treatment outcomes and quality of life throughout the course of the disease.

Complements tissue biopsy

Liquid biopsy, as a non-invasive testing option, complements tissue biopsy by revealing tumor heterogeneity, which may improve diagnostic and monitoring capabilities and improve diagnostic and treatment outcomes.

1. Lescuyer G, Harle A, Kumar HS, et al. medRxiv. 2024, doi: doi.org/10.1101/2024.10.17.24313324.

* SNV – single nucleotide variation, InDel – insertion or deletion, VAF – variant allele frequency.

What are the benefits of the HP2 test?

The HP2 test for circulating tumor DNA allows the physician to:

Understand

To detect cancer, determine the type, origin and severity of cancer.

Suggest

Treatment options appropriate for cancer genetic alterations.

Monitor

To determine the response of cancer to treatment, to determine recovery or relapse.

Investigated genes

A compact yet comprehensive 32-gene panel allows the detection of a variety of gene alterations in more than 10 of the most common cancers in a single liquid biopsy test.

The test is highly effective because over 80% of the genes in the panel are classified as the highest cancer gene rank (I ESCAT level), which reliably links gene changes to cancer diagnosis and effective treatment.

The gene panel also tests for:

  • MSI – 36 biomarkers of microsatellite instability
  • METex14 single exome skipping
  • EGFR VIII variant

The unique Hedera Dx gene analysis technologies used ensure high accuracy and reliability of the test [1].

The HP2 test allows the detection of cancer gene alterations in different cancer types:

NSCLC Colorectal Choloangio-carcinoma Gastric Thyroid Breast Prostate Pancreatic Hepato-cellular Ovarian Endometrial Urothelial Soft tissue carcinoma

EGFR

ALK

MET

KRAS

BRAF

RET

ROS1

NTRK1

BRAF

KRAS*

NRAS*

NTRK1

EGFR-ECD

ERBB2

MSI-H

IDH1

FGFR2

NTRK1

MSI-H

ERBB2

NTRK1

MSI-H

BRAF

RET

NTRK1

PIK3CA

ERBB2

ESR1

NTRK1

MSI-H

MSI-H

NTRK1

MSI-H

NTRK1

MSI-H

MSI-H

MSI-H

FGFR

FGFR3-TACC3

NTRK1

NTRK1

MET

ERBB2

BRAF

PTEN

* Mechanism of resistance not applicable to ESCAT, according to Pascual J, et al., Ann Oncol. 2022 Aug; 33(8):750-768

ESCAT level I genes

ESCAT level II genes

Test results

After the test, you will receive a report that will include all identified gene changes and recommended medications for the treatment of their consequences (in English). An interpretation of the test result in English will also be included. You can provide all the data received to your geneticist or oncologist.

Example of test results report (in English)

Where can I get the HP2 test?

Please contact us using the contacts provided.

 

Our partners
Cirkuliojančios vėžio DNR tyrimo HP2

atlikimui Lietuvoje

 

Our authorized partner
VeriSeq™ NIPT Solution v2
for conducting research in Lithuania